アブストラクト | Members of the dipeptidyl peptidase-4 inhibitor drug class are indicated for glycemic control in patients with type 2 diabetes mellitus and all, except linagliptin, require dose adjustment in renal impairment. A cross-sectional analysis of a cohort of type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors identified in the Clinical Practice Research Datalink was conducted to explore compliance with the renal adjustment requirements of the Summaries of Product Characteristics. Approximately one third of type 2 diabetes mellitus patients with creatinine clearance <50 mL/min who were at risk of inappropriate prescribing, were initiated on a DPP-4 inhibitor at a higher dose than the specified in their respective Summary of Product Characteristics. |
ジャーナル名 | Clinical therapeutics |
投稿日 | 2017/12/17 |
投稿者 | Spanopoulos, Dionysis; Barrett, Brendan; Busse, Michael; Roman, Toni; Poole, Chris |
組織名 | Boehringer Ingelheim Ltd, Berkshire, UK.;Eli Lilly and Company, Basingstoke, UK. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/29246708/ |